Core Viewpoint - The company has initiated a multi-dose escalation (MAD) Phase Ib trial for its second-generation glucose kinase activator (GKA), HMS1005, in the United States, marking a significant step in its development for treating type 2 diabetes (T2D) [1] Group 1: Clinical Trial Details - The trial is a randomized, double-blind, placebo-controlled study aimed at assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in T2D subjects [1] - The study will evaluate pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon, as well as monitor blood glucose fluctuations using continuous glucose monitoring (CGM) [1] Group 2: Drug Characteristics - HMS1005 is a novel molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow once-daily dosing, enhancing patient convenience and prolonging the drug's duration in the intestine [1] - The drug aims to improve the secretion of GLP-1, which is often insufficient in patients [1] Group 3: Future Plans - Upon successful completion of the MAD Phase Ib study, the company plans to seek partnerships for the global development of HMS1005 [1]
华领医药-B(02552)：第二代葡萄糖激酶激活剂(GKA)美国MAD Ib期试验首名患者已成功给药